Copyrights on musical compositions or novels typically last 50 to 70 years after the creator's death. It's a shame that this doesn't apply to drug firms, because Forest Labs (NYSE:FRX) is facing the unpleasant prospect of patent expiration for its two biggest-selling drugs - after which generic drugs can begin stealing market share and revenue.

Top Two Drugs Drew 90% Of Third-Quarter Sales
Forest has little hope of staving off either of these coming expirations to generic competition from the likes of Teva Pharmaceutical Industries (Nasdaq:TEVA) and Mylan (Nasdaq:MYL), which is scheduled for the depression treatment drug Lexapro in early 2012 and roughly a year later for Namenda, which is primarily used to treat Alzheimer's disease. This is unfortunate, as Lexapro accounted for 64%, or $585.5 million of total third-quarter net sales of $920 million, results of which were reported January 20. Namenda accounted for another 26% of sales, demonstrating the extent of the top-line hole Forest will have to dig itself out of in just a few short years. (For more on evaluating drug companies, check out Measuring The Medicine Makers.)

Can Pipeline Offset Upcoming Expiries?
Analyst opinions are mixed about whether Forest has a strong enough pipeline to offset the upcoming expiries. Bystolic, which is used to treat hypertension, was released on the market but posted Q3 sales of only $21 million, although Forest is readying new drug applications for additional usage such as treating congestive heart failure. Other products on the market, such as AeroBid, AeroChamber and Campral reported very small quarterly sales compared to Forest's two blockbuster drugs.

Management believes that its late-stage pipeline "could collectively represent several billion dollars of potential product sales in the long-term sufficient to replace the revenues lost to the patent expiries for Lexapro and Namenda combined". Of course, it also conceded that this scenario might not turn out to be quite so rosy. The company must keep the pedal to the metal in terms of its earlier-stage pipeline, continuing to work with partners in licensing drugs and potentially acquiring competitors, such as the January 2007 purchase of privately held biotech firm Cerexa. (Learn how to evaluate an acquisition in The Merger - What To Do When Companies Converge.)

Profit Potential Is Significant In Immediate Future
Forest could also turn into prey if a giant pharmaceutical firm such as Merck (NYSE:MRK) or Eli Lilly (NYSE:LLY) finds its pipeline prospects promising. Also appealing to potential suitors, Forest is sitting on approximately $2 billion in cash, no long-term debt and is churning out in excess of $1 billion in operating cash flow while Lexapro and Namenda remain patent-protected. In other words, profit potential is significant for the next couple of years as illustrated by the $188 million in Q3 net income, or 62 cents per share, or 19% of net sales.

Final Thoughts
Finally, Forest's valuation is low with a fiscal 2009 forward P/E multiple of just over 7 based on the $3.35-$3.45 earnings guidance that management provided when it released Q3 results. Uncertainty lurks when looking out past 2011, but a fair amount of downside is already priced into the shares. Plus, Forest can pull a number of levers to enhance shareholder value going forward, and unlike a large pharmaceutical company, a couple of successful drugs could have a significantly beneficial impact on sales and profits.

Related Articles
  1. Investing Basics

    Explaining Options Contracts

    Options contracts grant the owner the right to buy or sell shares of a security in the future at a given price.
  2. Home & Auto

    When Are Rent-to-Own Homes a Good Idea?

    Lease now and pay later can work – for a select few.
  3. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Derivative

    A security with a price that is dependent upon or derived from ...
  3. Security

    A financial instrument that represents an ownership position ...
  4. Series 6

    A securities license entitling the holder to register as a limited ...
  5. Internal Rate Of Return - IRR

    A metric used in capital budgeting measuring the profitability ...
  6. Board Of Directors - B Of D

    A group of individuals that are elected as, or elected to act ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. How does a forward contract differ from a call option?

    Forward contracts and call options are different financial instruments that allow two parties to purchase or sell assets ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!